



## **2008 Prohibited List**

### **Summary of Major Modifications**

#### **SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)**

##### S1. Anabolic Steroids

###### 1- Anabolic Androgenic steroids

- The concept of “atypical” result has been introduced in the explanatory text of this section:
  - 1- In the fourth paragraph, two additional sentences have been added to establish that if an initial result for an endogenous anabolic steroid triggers additional investigations in order to determine the endogenous or exogenous origin of the substance, then the sample should be reported as “*atypical*” instead of an “*Adverse Analytical Finding*”. This concept of “*atypical*” result is incorporated as follows: “*When such an investigation is required, the result shall be reported by the laboratory as atypical and not as adverse.*” and “*The result that triggered this longitudinal study shall be reported as atypical*”.
  - 2- The phrase “*and an Adverse Analytical Finding will be reported*” has been added to the first sentence of the first paragraph to indicate that this definition applies to a result that is not considered “atypical” and it has been proven to represent an *Adverse Analytical Finding*.
- Several sentences in the explanatory text have been deleted and text modifications have been introduced to avoid redundancies. In this regard:
  - 1- The phrase “*in order to determine whether the result is due to a physiological or pathological condition, or has occurred as a consequence of the exogenous origin of a Prohibited Substance*” has been deleted from the third paragraph and the concept has been summarized in changes introduced to the first sentence of the third paragraph: “*When a value does not so deviate from the range of values normally found in humans and any reliable analytical method.....*”.

- 2- The phrase *“When a laboratory has reported a T/E ratio greater than four (4) to one (1) and any reliable analytical method (e.g. IRMS) applied has not determined the exogenous origin of the substance, further investigation may be conducted by a review of previous tests or by conducting subsequent test(s), in order to determine whether the result is due to a physiological or pathological condition, or has occurred as a consequence of the exogenous origin of a Prohibited Substance.”* has been deleted from the fourth paragraph of the 2007 List and summarized in the first sentence of the third paragraph as *“..... or when a laboratory has reported a T/E ratio greater than four (4) to one (1) and any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance,”*.
- 3- The last sentence of the fifth paragraph of the 2007 List *“When an additional reliable analytical method (e.g. IRMS) has not been applied and a minimum of three previous test results are not available, a longitudinal profile of the Athlete shall be established by performing a minimum of three no advance notice tests in a period of three months by the relevant Anti-Doping Organization. If the longitudinal profile of the Athlete established by the subsequent tests is not physiologically normal, the result shall be reported as an Adverse Analytical Finding.”* has been deleted because this information is now redundant with previous paragraphs.

## 2 - Other anabolic agents

- The Selective androgen receptor modulators (SARMs) have been included in this section. This novel family of nonsteroidal molecules has been identified as being selective and specific for the androgen receptor. Therapeutic SARMs are currently being developed for the treatment of muscle wasting diseases and androgen replacement therapies. Based upon their mechanisms of action and early clinical results in humans, these compounds have the potential to be used as doping substances.

## S2. Hormones and Related Substances

- To be consistent with the presentation of the other sections, the introductory sentence was split in two before and after the list of examples.
- It is noted that LH and hCG are just 2 examples of Gonadotrophins by adding “e.g.”
- An “s” has been added to Insulin to reflect the availability of long and short acting types of insulin.

- The last paragraph of the section has been deleted to avoid redundancies with *“including other substances with similar chemical structure or similar biological effect(s)”*.

#### S4. Hormones Antagonists and Modulators

- In order to broaden the spectrum of new substances that antagonize and/or modulate hormone receptors, the title of the S4 section, formerly “Agents with Anti-Estrogenic activity” has been changed to “Hormone Antagonists and Modulators”.
- Agents modifying myostatin functions, which can antagonize and/or modulate the effects of myostatin or its signalling pathways (e.g. myostatin inhibitors) have been added to this section.

### **PROHIBITED METHODS**

#### M2. Chemical and Physical Manipulation

- Based on comments from stakeholders, the wording has been changed in order to clarify that the method can be used only in an acute medical situation. The intervention has to be justified by obtaining a retroactive Therapeutic Use Exemption.

### **SUBSTANCES PROHIBITED IN PARTICULAR SPORTS**

#### P1. Alcohol

- At the request of the CMSB (Boules), this Federation is removed from this section.

#### P2. Beta-blockers

- At the request of the UIM, Powerboating is included in this List, as it is considered that these drugs can be used to enhance performance in this particular sport.

### **SPECIFIED SUBSTANCES**

- It is clarified that the beta-2-agonist clenbuterol is listed in the S1.2 section as Other Anabolic Agents.

- Alpha reductase inhibitors (e.g. finasteride, dutasteride) are now considered Specified Substances. Although these drugs can be used as masking agents for androgenic steroids, recent research data demonstrate that there are analytical ways to determine whether they have been used in conjunction with steroids by detailed analysis of the androgenic steroid profile.